Wellington Management Group LLP Sells 9,807 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Wellington Management Group LLP trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 63,513 shares of the biopharmaceutical company's stock after selling 9,807 shares during the period. Wellington Management Group LLP's holdings in TG Therapeutics were worth $1,912,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in TGTX. O Shaughnessy Asset Management LLC acquired a new stake in TG Therapeutics during the fourth quarter valued at approximately $259,000. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics during the 4th quarter worth approximately $55,237,000. New Age Alpha Advisors LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at $213,000. Norges Bank bought a new stake in TG Therapeutics in the fourth quarter valued at $12,085,000. Finally, Segall Bryant & Hamill LLC increased its position in shares of TG Therapeutics by 51.8% during the 4th quarter. Segall Bryant & Hamill LLC now owns 79,518 shares of the biopharmaceutical company's stock worth $2,393,000 after purchasing an additional 27,128 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 0.3 %

Shares of NASDAQ TGTX traded up $0.11 during mid-day trading on Friday, hitting $38.32. The company's stock had a trading volume of 1,074,546 shares, compared to its average volume of 3,106,858. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.32. The company's fifty day simple moving average is $36.34 and its 200-day simple moving average is $31.85. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market cap of $6.02 billion, a price-to-earnings ratio of -383.16 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.